Abstract Submissions are now closed.
|September 3||Deadline to become an AHA/ASA Professional Member to receive early registration rates|
|September 17||Deadline for early registration rates|
|October 1||Deadline to become an AHA/ASA Professional Member to receive member registration discount|
|October 15||Deadline for advance registration rates|
|October 16||Standard registration rates apply|
The American Heart Association’s Scientific Sessions has the best science and is the leading cardiovascular conference for basic, translational, clinical and population science, in the United States.
Scientific Sessions attracts more than 17,000 attendees, with a global presence from more than 100 countries. In addition to 1.5 million medical professionals who participated virtually in lectures and discussions about basic, translational, clinical and population science.
Programming is designed to improve patient care by communicating the most timely and significant advances in basic, clinical, translational and population health research, spanning the full spectrum of cardiovascular disease from a variety of perspectives, from prevention, through diagnosis and through treatment. Sessions includes five days of comprehensive, unparalleled education through more than 5,000 presentations, with 1,000 invited faculty, and 4,000 abstract presentations; all from the world’s leaders in cardiovascular disease. It also includes more than 200 exhibitors showcasing the latest cardiovascular technology and resources.
Lead the way to discovery in the fight against cardiovascular disease and stroke.
|For an authoritative reference of the key findings from the American Heart Association’s Scientific Sessions 2013, we invite you to read the official peer-reviewed highlights report.|
The top advances from key clinical trials in this report include summaries from the ENGAGE AF-TIMI 48, TOPCAT, CORAL and ERASE trials.
Feature articles provide an overview of updates to the AHA/ACC clinical guidelines for chronic heart failure and the development of personalized management of atrial fibrillation. Also included are therapeutic updates which contain in depth information on the 2013 AHA/ACC guidelines for the prevention of atherosclerotic cardiovascular disease, the management of patients with heart failure and diabetes, and cancer treatment and cardiovascular disease.